Patients with immune-mediated diseases need oral medicines that are both effective and more selective than broad immunosuppressants.
R&D Focus
Precision immunology; TYK2 inhibition; data analytics for autoimmune-disease drug discovery.
Innovative Solution
Alumis applies a precision-data analytics platform to discover and develop oral therapies, led by the allosteric TYK2 inhibitor envudeucitinib and other clinical candidates.
Solution Effectiveness
In company-reported Phase 3 psoriasis results, about 65% of patients achieved PASI 90 and more than 40% achieved clear skin at 24 weeks. These are clinical-trial results, not agriculture outcomes.
Alumis develops precision medications to treat autoimmune illnesses. The company’s analytics platform and understanding of immunologic disorders aid in the development of treatments and medications for autoimmune diseases, allowing patients to alleviate suffering and modify their way of life.
Products
Product
Envudeucitinib, A-005 and lonigutamab: investigational medicines for immune-mediated diseases.
Star Product
Envudeucitinib – the most advanced programme and the company’s principal near-term regulatory asset.
Demo Product or Complete Product?
Late-stage clinical products, not an agriculture product. Envudeucitinib is in Phase 3 development; the company indicated a planned FDA filing in the second half of 2026.
Future Plan
Market Expansion
Plans concern clinical development and potential regulatory filings in global pharmaceutical markets, not agriculture.
Investment Funding
Public-company financing is disclosed through SEC filings and investor materials. No agriculture-related fundraising plan applies.
Awards and Recognitions
Participations
Public biotechnology company conducting multiple Phase 2 and Phase 3 clinical programmes.
Media Apperance
Covered in biotechnology and financial media for Phase 3 results and regulatory plans.
M&A and Collabs
Collab
No agriculture collaboration identified. Clinical and research relationships are focused on biotechnology and autoimmune disease.
Acquisitions
Alumis was formed through the evolution of Esker Therapeutics and completed a merger with ACELYRIN in 2025; this is a corporate combination rather than an agriculture acquisition.
Something missing or incorrect on this page? Help us enrich this information
